Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07578571 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Immunome.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT07578571 is a Phase 1 study that is actively recruiting participants, run by Immunome. The registered enrollment target is 175 participants.
The verdict
NCT07578571, a Phase 1 study, is actively recruiting participants, sponsored by Immunome.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.
Interventions
- DRUG IM-1617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07578571
The ClinicalTrials.gov registry entry for NCT07578571 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IM-1617 is the first listed.
NCT07578571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07578571 about?
NCT07578571 is a clinical study titled "A Phase 1 Study of IM-1617 in Participants With Advanced Cancer". This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in...
What is the current status of trial NCT07578571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2026-05-21. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07578571?
The interventions under investigation include: IM-1617 (DRUG).
Who is sponsoring clinical trial NCT07578571?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.